Skip to main content
. Author manuscript; available in PMC: 2022 Jun 13.
Published in final edited form as: JAMA Oncol. 2022 Feb 1;8(2):287–291. doi: 10.1001/jamaoncol.2021.5153

Figure 2:

Figure 2:

Figure 2:

Figure 2:

Figure 2:

A) Event history for overall survival from diagnosis among stage IV NSCLC patients (N=727). Each patient’s survival time from diagnosis is indicated by a blue line with a black line overlaid to illustrate duration of delayed study entry. B) Kaplan-Meier curves illustrating overall survival from diagnosis among stage IV NSCLC patients with and without adjustment for delayed study entry. C) Event history for overall survival from most common first-line regimen among stage IV NSCLC patients (N=137). Each patient’s survival time from start of regimen is indicated by a blue line with a black line overlaid to illustrate duration of delayed study entry. D) Kaplan-Meier curves illustrating overall survival from start of most common first-line regimen among stage IV NSCLC patients with and without adjustment for delayed study entry.